A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting

Phase 1

Glofitamab, Gemcitabine, OxaliplatinA Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sponsor:

Hoffmann-La Roche

Code:

NCT06624085

Conditions

Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Glofitamab

Tocilizumab

Obinutuzumab

Gemcitabine

Oxaliplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-12. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2025-11-10.